1. Escape from flatland: increasing saturation as an approach to improving clinical success;Lovering;J. Med. Chem.,2009
2. Reboxetine is approved and marketed as a mixture of the (R, R)-(-) enantiomer shown and the corresponding (S, S)-(+) enantiomer.
3. New substituted azaindoline derivatives as NIK inhibitors. World Intellectual Property Organization;Hynd;Pat. Appl. WO,2019
4. Preparation of (ethylsulfonyl)benzyl morpholinylarylcarboxamides as inhibitors of RORγt for potential use in treating inflammatory and autoimmune diseases;Lingam;World Intellectual Property Organization Pat. Appl. WO,2018
5. Preparation of pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer. World Intellectual Property Organization Pat;Ye;Appl. WO,2018